Category: elsevier

Update on the Gressner case: Son Olav says he’s the unfairly targeted “bête noire”

We have an update on the case of Olav and Axel Gressner, a father-son (or, in this case, son-father) pair of German liver researchers caught up in a fraud investigation. The inquiry focused on Olav, who left the University of Aachen under a cloud of suspicion. A 2008 research letter on which he was a co-author (his father was senior author) was retracted earlier this year by the Journal of Hepatology.

The journal’s position in the retraction notice,  published online in June and in print in September, bears repeating here. The authors: Continue reading Update on the Gressner case: Son Olav says he’s the unfairly targeted “bête noire”

Academic purgatory: Papers withdrawn before they’re “officially” published

If a paper appears online but then is withdrawn — a kinder, gentler version of retracted — before it is “officially” published, did anyone hear it fall?

Oops, mixed metaphors again. And scare quotes! The latter, however, are because publishers seem to have varying opinions of whether or not something that is freely available online is published. And that has ramifications for whether you can retract a paper like that.

Let us explain with two examples: Continue reading Academic purgatory: Papers withdrawn before they’re “officially” published

More on the latest Cell retraction: PI says a graduate student was at fault

Carsten Carlberg

This morning we reported on a new retraction in Cell involving fraud from a lab in Finland, which led us to a second retraction of a paper by the same group in the Journal of Molecular Biology. The first author on both papers was Tatjana Degenhardt, who at the time was a graduate student in the lab of Carsten Carlberg, professor of biochemistry at the University of Kuopio.

A few minutes ago Retraction Watch spoke with Carlberg, who had this to say about Degenhardt: Continue reading More on the latest Cell retraction: PI says a graduate student was at fault

Third retraction for Indiana University scientist who altered figures in NIH-funded research

Another shoe has dropped in the case of Emily M. Horvath, the Indiana researcher whose tinkering with figures while on a $369,000 federal grant ended in sanctions by government officials.

Biochemical and Biophysical Research Communications, an Elsevier title, has retracted another paper on which Horvath was an author, bringing to three the number of her articles tainted in the scandal. The paper, “A novel membrane-based anti-diabetic action of atorvastatin,” was published online in June 2008, and cited four times since, according to Thomson Scientific’s Web of Knowledge. (Atorvastatin is sold as Lipitor.) According to the journal: Continue reading Third retraction for Indiana University scientist who altered figures in NIH-funded research

Scientist raised serious questions about 2008 Cell study by Amy Wagers

Amy Wagers, a Harvard stem cell researcher, retracted a Nature study last week and has another published paper under scrutiny at Blood. Retraction Watch has now learned that a 2008 Cell paper she co-authored drew significant criticism from a stem cell researcher at Children’s National Medical Center.

In the paper, Wagers and her team said they were able to prepare a set of muscle cells that reversed some of the effects of muscular dystrophy in a mouse model of the disease. In a 2008 letter to the editor of Cell, however, Terence Partridge wrote Continue reading Scientist raised serious questions about 2008 Cell study by Amy Wagers

Editor of another journal where Wagers and Mayack published an abstract is monitoring the situation

Yesterday, we noted that Amy Wagers and Shane Mayack have published five papers together. One of those, published earlier this year in Nature, was retracted Wednesday, and another is now the subject of a “notice of concern” from Blood.

We wanted to find out about some of the other papers published by Wagers and Mayack, so we contacted the editor of Developmental Biology, which published one of them. They have not heard from Wagers or Harvard, but are monitoring developments, according to editor in chief Robb Krumlauf: Continue reading Editor of another journal where Wagers and Mayack published an abstract is monitoring the situation

Beyond retractions: A technique gets an obituary

Sometimes, apparently, a retraction isn’t enough to put research findings to bed forever. Consider this obituary recently posted online at the Journal of Pediatrics, for a method of detecting gastroesophageal reflux disease (GERD) in children:

We commonly recognize the contributions of distinguished members of the pediatric community and, with regret, their passing. It is appropriate, therefore, that we acknowledge the timely death of an old friend, the pH probe. Crushed to death under the weight of evidence against it, it was found abandoned in a trash can with a note that read, ‘‘Good riddance to a bad test.’’

To be fair, the pH probe has always been the standard bearer for mediocrity.

The obituary goes on: Continue reading Beyond retractions: A technique gets an obituary

Microbial reproduction: Plagiarism from Wikipedia, elsewhere leads to retraction of biotech paper

When is an advance not an advance?

Biotechnology Advances has retracted a 2008 review by researchers in India who allegedly stole chunks of their manuscript from several sources including journal articles, Wikipedia, and StateMaster.com, a statistics clearinghouse.

According to the notice, the article, titled “Microbial production of dihydroxyacetone” Continue reading Microbial reproduction: Plagiarism from Wikipedia, elsewhere leads to retraction of biotech paper

Best Of Retractions, Part I: Water, water, everywhere, except in “Historical Palestine,” aka Israel

Although Retraction Watch might have been born just before yesterday, we find it instructive to look back in time for items we would have covered had we been around a bit longer. We’ll do this periodically to generate a “Best Of” collection of retractions that catch our eye both for what they might suggest about scientific publishing and for good old-fashioned  interest. Here’s the first installment:

A furtive attempt to play politics with a galley proof led to the retraction of a paper on Middle East water policy a few months ago. The article, “Optimizing irrigation water use in the West Bank, Palestine,” appeared in the February 2010 issue of Agricultural Water Management, an Elsevier journal. Written by Palestinian and Dutch researchers, the article modeled various scenarios of water and crop policies in the West Bank in an effort to determine the most efficient use of resources.

But a funny thing happened on the way to the printer. The authors decided to make a political protest of sorts in the galleys, a ham-handed gesture that led to the retraction of the paper, as the journal explained in a note: Continue reading Best Of Retractions, Part I: Water, water, everywhere, except in “Historical Palestine,” aka Israel

Update on stem cell-cancer link retraction: Why not everyone signed, and why authors ended up in another journal first

Last month, we wrote about the retraction of a 2005 paper suggesting that some adult stem cells might give rise to cancer. That, of course, would be a problem if researchers tried treating heart disease and other conditions with them. The paper’s authors retracted it, however, when it became clear that instead of being transformed — that’s the scientific word for “became cancerous” — the cells had simply become contaminated and overgrown with tumor cells used in research.

We had some questions for the authors of the original paper, and for the editor of the journal. Last week, we heard back from one of the paper’s authors, Javier Garcia-Castro, who had been on vacation without Internet access for weeks. In an email to Retraction Watch, Garcia-Castro wrote: Continue reading Update on stem cell-cancer link retraction: Why not everyone signed, and why authors ended up in another journal first